209 related articles for article (PubMed ID: 21871459)
1. Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
Lenski M; Kazakov A; Marx N; Böhm M; Laufs U
J Mol Cell Cardiol; 2011 Dec; 51(6):906-18. PubMed ID: 21871459
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats.
Giannocco G; Oliveira KC; Crajoinas RO; Venturini G; Salles TA; Fonseca-Alaniz MH; Maciel RM; Girardi AC
Eur J Pharmacol; 2013 Jan; 698(1-3):74-86. PubMed ID: 23051671
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
4. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
[TBL] [Abstract][Full Text] [Related]
5. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.
Kim YS; Oh SH; Park KS; No H; Oh BJ; Kim SK; Jung HS; Kim JH; Lee MS; Lee MK; Kim KW
Pancreas; 2011 Aug; 40(6):855-60. PubMed ID: 21747318
[TBL] [Abstract][Full Text] [Related]
7. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
8. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
10. Cardiac expression of adiponectin and its receptors in streptozotocin-induced diabetic rats.
Guo Z; Xia Z; Yuen VG; McNeill JH
Metabolism; 2007 Oct; 56(10):1363-71. PubMed ID: 17884446
[TBL] [Abstract][Full Text] [Related]
11. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4.
Hamdani N; Hervent AS; Vandekerckhove L; Matheeussen V; Demolder M; Baerts L; De Meester I; Linke WA; Paulus WJ; De Keulenaer GW
Cardiovasc Res; 2014 Dec; 104(3):423-31. PubMed ID: 25341892
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
15. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
16. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
17. Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
Yeom JA; Kim ES; Park HS; Ham DS; Sun C; Kim JW; Cho JH; Yoon KH
BMB Rep; 2011 Nov; 44(11):713-8. PubMed ID: 22118536
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure.
Gomez N; Touihri K; Matheeussen V; Mendes Da Costa A; Mahmoudabady M; Mathieu M; Baerts L; Peace A; Lybaert P; Scharpé S; De Meester I; Bartunek J; Vanderheyden M; Mc Entee K
Eur J Heart Fail; 2012 Jan; 14(1):14-21. PubMed ID: 22045924
[TBL] [Abstract][Full Text] [Related]
19. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
[TBL] [Abstract][Full Text] [Related]
20. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation.
Ong KW; Hsu A; Tan BK
Biochem Pharmacol; 2013 May; 85(9):1341-51. PubMed ID: 23416115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
